Digestive Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology IRCCS, Milan, Italy.
Eur J Surg Oncol. 2023 Nov;49(11):107069. doi: 10.1016/j.ejso.2023.107069. Epub 2023 Sep 9.
Tumour-specific mesorectal excision (TSME) practice for rectal cancer only relies on small retrospective studies. This study aimed to perform a systematic review and meta-analysis to assess the oncological and functional outcomes of TSME practice.
A systematic review protocol was drawn to include all the studies that compared partial versus total mesorectal excision (PME vs TME) practised for rectal adenocarcinoma up to 16 cm from the anal verge. A systematic literature search was conducted on EMBASE-Medline, Pubmed and Cochrane Library. Reports were screened for the study's outcomes: oncological radicality, postoperative anastomotic leak risk and functional outcomes. Included studies were appraised for risk-of-bias and meta-analysed. Evidence was rated with the GRADE approach.
Twenty-seven studies were included, consisting of 12325 patients (PME n = 4460, 36.2%; TME n = 7865, 63.8%). PME was performed for tumours higher than 10 cm from the anal verge in 54.5% of patients. There was no difference between PME and TME in circumferential resection margin positivity (OR 1.31, 95%CI 0.43-3.95, p = 0.64; I = 38%), and local recurrence risk (HR 1.05, 95%CI 0.52-2.10, p = 0.90; I = 40%). The postoperative leak risk (OR 0.42, 95%CI 0.27-0.67, p < 0.001; I = 60%) and the major low anterior resection syndrome risk (OR 0.34, 95%CI 0.28-0.40, p < 0.001; I = 0%) were lower after PME surgery. No difference was found in urinary incontinence (OR 0.68, 95%CI 0.13-3.67, p = 0.66) and urinary retention after early catheter removal (OR 2.00, 95%CI 0.24-16.51, p = 0.52).
Evidence from this meta-analysis shows that TSME for rectal cancer has good oncological results and leads to the best-fitted functional results possible for the patient's condition.
肿瘤特异性直肠系膜切除术(TSME)在直肠癌中的应用仅依赖于一些小型回顾性研究。本研究旨在进行系统回顾和荟萃分析,以评估 TSME 实践的肿瘤学和功能结果。
制定了系统评价方案,纳入了所有比较部分直肠系膜切除术(PME)与全直肠系膜切除术(TME)治疗距肛门 16cm 以内直肠腺癌的研究。对 EMBASE-Medline、Pubmed 和 Cochrane 图书馆进行了系统文献检索。报告的研究结果包括:肿瘤学根治性、术后吻合口漏风险和功能结果。对纳入的研究进行了偏倚风险评估,并进行了荟萃分析。证据采用 GRADE 方法进行评估。
共纳入 27 项研究,包括 12325 例患者(PME 组 n=4460,36.2%;TME 组 n=7865,63.8%)。在 54.5%的患者中,PME 用于距肛门 10cm 以上的肿瘤。在环周切缘阳性率(OR 1.31,95%CI 0.43-3.95,p=0.64;I²=38%)和局部复发风险(HR 1.05,95%CI 0.52-2.10,p=0.90;I²=40%)方面,PME 与 TME 无差异。PME 术后吻合口漏(OR 0.42,95%CI 0.27-0.67,p<0.001;I²=60%)和主要低位前切除综合征风险(OR 0.34,95%CI 0.28-0.40,p<0.001;I²=0%)较低。PME 术后尿失禁(OR 0.68,95%CI 0.13-3.67,p=0.66)和早期导管拔除后尿潴留(OR 2.00,95%CI 0.24-16.51,p=0.52)无差异。
本荟萃分析的证据表明,直肠癌的 TSME 具有良好的肿瘤学结果,并为患者的病情提供最佳的功能结果。